Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate a radiolabeled urea-based small molecule inhibitor
of prostate-specific membrane antigen (PSMA), [18F]DCFPyL (DCFPyL) PET/CT (or PET/MRI imaging
if available) for detection of metastatic prostate cancer. PSMA is a well characterized
histological marker of prostate cancer tumor aggressiveness and metastatic potential.
Preliminary first-in-human studies demonstrate high specific uptake of a first generation
less avid compound, DCFBC, in metastatic prostate cancer and demonstrated feasibility for
prostate cancer metastatic detection. Investigators propose to assess the ability of DCFPyL
PET to detect metastatic prostate cancer by visual qualitative and quantitative SUV analysis.
Correlation will be made to sites of suspected metastatic disease detected by ultra sensitive
but less specific [18F]Sodium Fluoride (NaF)-PET/CT imaging for prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins